Clinical trial
IMFINZI® Injection 120 mg, 500 mg Specific-Clinical Experience Investigation in Patients With Extensive Stage Small Cell Lung Cancer
NCT04854590 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- IMFINZI® Injection 120 mg, 500 mg Specific-Clinical Experience Investigation in Patients With Extensive Stage Small Cell Lung Cancer
- Lead sponsor
- AstraZeneca
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 22, 2021
- Completion date
- July 25, 2023
- Enrollment
- 248 (actual)
- Sites
- 18
Conditions
As the registry lists them; a condition with its own page is linked.